© 2021 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Diabetes
Today’s Effects of Telehealth When Caring for Diabetic Children
April 23, 2021
Dr. Kathleen Bethin, clinical professor, and Dr. Lucy Mastrandrea, associate professor and division chief of endocrinology/diabetes both at the Jacobs School of Medicine & Biomedical Sciences at the University at Buffalo, spoke with Vic Baldry of Cecelia Health to discuss the challenges telehealth has created when caring for families with children who have type 1 diabetes.
SGLT2 Inhibitor Use Stunted for Black, Female, Lower Income Type 2 Diabetes Patients
April 21, 2021
Access to care and other health disparities result in the low use of novel therapies for Black, female and lower income type 2 diabetes patients. If these barriers aren't addressed, disparities among kidney and cardiovascular patients may worsen in the U.S.
Inside Chronic Diseases: COVID-19 and Diabetes
February 10, 2021
Diabetes education has shifted from in-person classes to Zoom meetings.
Glucose Lowering Medications Less Likely Among Medicare Advantage Beneficiaries
February 01, 2021
Commercial health insurance plan enrollees are more likely to take glucose-lowering medications.
Majority of Diabetes Patients Would Adopt Remote Digital Monitoring
January 13, 2021
The findings are encouraging for future use of remote digital monitoring.
Digital Health App for Diabetes May Reduce Healthcare Costs
December 16, 2020
Digital health apps offer solutions to improve diabetes self-management.
AHA: Fauci Says Long-term Follow Up Needed to Understand COVID-19 Effects
November 18, 2020
Dr. Anthony Fauci addresses the American Heart Association Scientific Sessions.
After Setbacks, Good News for Sotagliflozin in Heart Failure, CKD
November 17, 2020
After an FDA denial and a lost sponsor, sotagliflozin shows it can cut cardiovascular events and possibly treat a form of heart failure that has no approved therapies.
AHA: Four in Five Heart Failure Patients Fit Criteria for Farxiga
November 13, 2020
The findings are the first in a series of six studies involving a registry supported by drug makers in the diabetes, cardiovascular, and heart failure space.